Navigation Links
Astellas Oncology Announces New Data in Acute Myeloid Leukemia to be Presented at the 2016 ASH Annual Meeting
Date:11/17/2016

NORTHBROOK, Ill., Nov. 17, 2016 /PRNewswire/ -- Astellas today announced two gilteritinib abstracts, including an oral presentation in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML), that will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition, Dec. 3-6 in San Diego.

The following abstract will be presented during an oral presentation session:

Continue Reading
Astellas is a pharmaceutical company dedicated to improving the health of people around the world.
Astellas is a pharmaceutical company dedicated to improving the health of people around the world.

Title: Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML). (Abstract 1069)

Presenter: Alexander E. Perl, M.D., University of Pennsylvania-Abramson Comprehensive Cancer Center, Philadelphia, Pa.

  • Session Date/Time: Monday, Dec. 5 at 4:30 p.m. PST
  • Location: San Diego Ballroom AB (Marriott Marquis San Diego Marina)

In addition to the oral presentation, Astellas will present the following abstract in a poster session:

Title: Gilteritinib (ASP2215), a Novel FLT3/AXL Inhibitor: Preclinical Evaluation in Combination with Azacitidine in Acute Myeloid Leukemia (Yoko Ueno, PhD) (Abstract 2830)

  • Session Date/Time: Sunday, Dec. 4 from 6:00 p.m. to 8:00 p.m. PST
  • Location: Hall GH (San Diego Convention Center)

About Astellas

Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at www.astellas.us. You can also follow us on Twitter at @AstellasUS, Facebook at www.facebook.com/AstellasUS or LinkedIn at www.linkedin.com/company/astellas-pharma.

Logo - http://photos.prnewswire.com/prnh/20140416/84970

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/astellas-oncology-announces-new-data-in-acute-myeloid-leukemia-to-be-presented-at-the-2016-ash-annual-meeting-300365503.html


'/>"/>
SOURCE Astellas
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Astellas ontvangt handelsvergunning voor VESOMNITM van Nederlandse College ter Beoordeling van Geneesmiddelen
2. Amgen And Astellas Announce Japan Alliance
3. Molly Fletcher to Speak at Astellas Presents Executive Womens Day at the FedEx St. Jude Classic
4. Astellas Signs Distribution Agreement With Tecnofarma For Enzalutamide In Latin America
5. Molly Fletcher to Speak at Astellas Presents Executive Womens Day at the AT&T National
6. Dr. Helen Fisher to Speak at Astellas Presents Executive Womens Day at the Constellation SENIOR PLAYERS Championship
7. Astellas Appoints New Senior Vice President of Global Oncology Development
8. Astellas Confirms Interim Analysis in PREVAIL Study of XTANDI will Occur within Calendar Year 2013
9. Astellas to Host Executive Womens Day at 2013 TOUR Championship by Coca-Cola
10. Astellas Employees to Change Tomorrow through Annual Day of Service
11. Astellas US Appoints Senior Vice President, Chief Communications Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2018)... (PRWEB) , ... August 10, 2018 , ... Dry eye ... Some of these products are excellent, and they do provide some relief from dry ... use than a product created and marketed by a small company in tiny Grants ...
(Date:8/11/2018)... SAN FRANCISCO (PRWEB) , ... August 11, 2018 ... ... Left Handers Day on Monday, August 13, with fun, games and gifts. Left-Handers ... in a world designed for right-handers. Having endured centuries of prejudice, countless indignities ...
(Date:8/9/2018)... ... 2018 , ... Autism is a developmental disorder affecting more than 3.5 million ... 1 in 68 people have the disorder), chances are you know someone on the ... child with autism methods of communication and tactics to interact with others. These options ...
Breaking Medicine Technology:
(Date:8/3/2018)... ... August 03, 2018 , ... Firstaid4sport ... Gerry Newlove first started the Firstaid4sport business in the 1990's and his son ... one of the leading providers in the UK of sports medicine products, supplying ...
(Date:8/3/2018)... ... August 03, 2018 , ... Lucyd Pte Ltd, ... announce the launch of its online store. The Lucyd eShop will feature the ... innovations in spectacles. , The eShop will have a number of unique ...
(Date:8/2/2018)... Calif. (PRWEB) , ... August 02, 2018 , ... ... be featuring its premium Resona 7 Ultrasound system with unique new upgrades at ... San Antonio, Texas. Based on ZONE Sonography® Technology (ZST), the upgrades include a ...
(Date:8/2/2018)... ... August 02, 2018 , ... A new ... topics in acute pain management. In The Role of Acute Care in the ... Engagement Network—an innovative approach to the opioid epidemic launched in the state of ...
(Date:8/2/2018)... ... ... Continuing their momentum in 2018 Sempulse has been selected as one of ... Ecliptic Capital, Mike W. Erwin, an early investor in Sempulse is bullish on the ... over 30 years starting companies and investing locally. The ideas, innovation and funding coming ...
Breaking Medicine News(10 mins):